William Ho

Company: IN8Bio

Job title: CEO

Seminars:

Sharing Results of Allogeneic Gamma Delta Therapy in AML Patients 4:00 pm

Discussing the rationale for developing chemo-resistant gamma delta therapy and clinical trial design as an adjuvant with current standard-of-care Choosing indications based on medical need and biological features of gamma delta T cells Presenting clinical results from phase 1 studies, highlighting efficacy and toxicity dataRead more

day: Day One